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HIV infection produces immune activation [1,2], 
and it is important to remember that HIV is the 
causative agent of chronic viral infection. This 
activation leads to immune deficiency through 
the destruction of target cells, and also induces 
some other pernicious consequences, such as 
low thymic output, lymphoid tissue fibrosis and 
T- and B-cell dysfunction. Other more long-term 
effects are represented by inflammation, tissue 
damage and coagulopathy, including an increase 
in non-AIDS morbidity and mortality [3].
This is what the natural history of HIV would 
be without antiretroviral (ARV) drugs, which 
target several steps in the HIV lifecycle. ARV 
treatment promotes lymphocyte redistribution via 
multiple phenomena: a biphasic increase in circu-
lating CD4 T cells [4] and a redistribution from 
lymph nodes to circulation [5]. Together with the 
effect on the immune system, ARV drugs suppress 
HIV viral replication, thus speeding up immune 
recovery. Notwithstanding prolonged suppression 
of viral load, approximately 15–30% of ARV-
treated subjects lack CD4 T-cell increase [6]. A 
French study found that 17% of HIV-infected 
subjects initiating a protease inhibitor-based regi-
men had an increase of <50 CD4 lymphocytes/µl 
after 6 months, despite attaining control of viral 
replication [7]. These subjects, who are defined 
as immuno logical nonresponders (INRs), have 
an increased risk of clinical progression to AIDS 
and death [8–10]. The ART Cohort Collaboration 
found that subjects with CD4 T cells <200/µl 
6 months after ART initiation were at a signifi-
cantly higher risk of AIDS or death, compared 
with those who had CD4 T cells >200/µl [11]. 
Other studies have also demonstrated that CD4 
counts are related to overall mortality and inci-
dence of non-AIDS cancers, even in subjects with 
CD4 lymphocytes >350/µl [12,13].
Moreover, the immune system could be 
diverted from its function against HIV by 
the presence of other comorbidities, such as 
chronic HCV infection [14] or underlying CMV 
infection [15].
Physicians caring for INR HIV-infected 
subjects struggle between two opposite 
options: leave ARV therapy as it is or start an 
experimental therapy in order to improve CD4 
count and functionality. In general, one main 
concern is the long -standing duration of immune 
suppression. Patients do not show any change in 
CD4 cell counts and this leads to concern that 
some unexpected event is going to irreversibly 
compromise the health of the patient. Indeed, 
the cited literature demonstrates multiple risks. 
However, together with the many worries, we 
should study, research and understand the rea-
sons why an expected phenomenon (i.e., the 
rise in CD4) is not occurring in the subjects we 
care for, notwithstanding optimal therapeutic 
adherence. Above all, we should consider two 
different standpoints. The first being immuno-
pathogenetic: identification and comprehension 
of the mechanisms of immunological failure, 
and the second being clinical and therapeutic: 
screening for the main comorbidities and 
possibly proceeding with an intensification of 
anti-HIV treatment.
“…we should study, research and 
understand the reasons why an 
expected phenomenon … is not 
occurring in the subjects we care for, 
notwithstanding optimal therapeutic 
adherence.”
Some therapeutic trials for therapeutic 
intervention in INR have been completed 
(e.g., atorva statin and hydroxy chloroquine), 
while others are underway or have been 
proposed, such as rifaximin, IL-7, antifibrotic 
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agents, maraviroc (MVC) and probiotics. In 
the past, IL-2 has been tested with the aim of 
increasing the number and function of CD4 
lymphocytes, but this strategy did not produce 
long-term positive results [16]. Among the most 
promising novel strategies in this field, IL-7 
seems to be useful in overcoming the impasse 
in the immune system in INR and clinical trials 
have been planned and completed [17]. Recently, 
MVC has been tested in three clinical trials. 
The first study, conducted by Peter Hunt at 
University of California, San Francisco (UCSF; 
CA, USA) did not indicate a significant increase 
in CD4 counts. Moreover, this trial indicated a 
rise in lymphocyte activation markers after the 
intensification with MVC [18]. The second study 
has been coordinated by the University of Milan 
(Italy). In this trial, MVC showed the ability 
to significantly increase IL-7 levels in plasma 
and the capacity to cause an increase in the 
number of CD4 lymphocyte, but only in sub-
jects with baseline CD4 <200/µl after 48 weeks 
of intensification [19]. The third study, ACTG 
A5256, did not show an increase in CD4 T-cell 
counts of at least 20 cells/µl after adding MVC 
to a virologically successful therapy for 24 weeks. 
In parallel, markers of immune activation and 
apoptosis decreased during MVC intensification, 
and this decline partially reversed after MVC 
discontinuation [20]. Overall, these results did 
not demonstrate the absolute benefit of adding 
MVC in HIV-infected subjects with an incom-
plete immunological recovery, although other 
immunomodulatory properties of MVC could 
be explored, such as the prevention of binding 
of b-chemokines and HIV gp120 to CCR5. 
This could probably explain the increase in 
CD4 lymphocytes in subjects with a dual/mixed 
(D/M)-tropic virus and an incomplete control 
of viral replication [21].
“…[the] results did not demonstrate the 
absolute benefit of adding maraviroc in 
HIV-infected subjects with an incomplete 
immunological recovery…”
If the blockade of CCR5 is not yet cer-
tain, another fascinating hypothesis is the 
administration of probiotics with the aim of 
prevent ing microbial translocation and hamper-
ing the increase in lipopolysaccharides plasma 
level seen in INR [22]. Of note, it has recently 
been shown that CD4 T cells in the jejunum 
increase at a faster rate, CD4 T-cell frequencies 
in the colon are higher and activated CD4 T-cell 
frequencies in the colon are lower with ARV plus 
probiotic treatment in pigtail macaques acutely 
infected with SIVmac239 [23].
Although there are many new approaches to 
treat the immunological nonresponse to ARV 
drugs in HIV infection, the principal effort 
should be directed towards finding new HIV 
infections and treating earlier – according to the 
‘test-and-treat’ strategy – in order to prevent a 
deeper depression of the immune system in both 
quantitative and qualitative terms.
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